Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hysteroscopy and laparoscopy with or without oral contraceptive pills for previous cesarean scar defect
ChiCTR2000032112Phase 4Not yet recruiting
- Sponsor
- Women's Hospital, Zhejiang University School of Medicine
- Start
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of drospirenone + ethinyl estradiol in Caesarean scar defect (CSD) (2 arms), sponsored by Women's Hospital, Zhejiang University School of Medicine. Primary endpoints: Menstruation time after operation, Uterus muscularis thickness and 1 more. Planned start Apr 2020; status: not yet recruiting.
02
Drugs
drospirenone + ethinyl estradiol
03
Conditions
Caesarean scar defect (CSD)
Beyond the preview
Go deeper on ChiCTR2000032112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032112.